about
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaExtent of resection and early postoperative outcomes following removal of cystic vestibular schwannomas: surgical experience over a decade and review of the literature.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaPhase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.A Perfusion-based Human Cadaveric Model for Management of Carotid Artery Injury during Endoscopic Endonasal Skull Base Surgery.Endoscopic endonasal transsphenoidal surgery: implementation of an operative and perioperative checklist.Facial reanimation: evolving from static procedures to free tissue transfer in head and neck surgery.Minimizing free flap donor-site morbidity.Factors Associated with Recurrence and Regional Adenopathy for Head and Neck Cutaneous Squamous Cell Carcinoma.Primary surgery for advanced-stage laryngeal cancer: A stage and subsite-specific survival analysis.Primary Surgery vs Chemoradiation Treatment of Advanced-Stage Hypopharyngeal Squamous Cell Carcinoma.Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom MacroglobulinemiaChanges in Head and Neck Oncologic Practice During the COVID-19 PandemicMental health among otolaryngology resident and attending physicians during the COVID-19 pandemic: National study
P50
Q24634360-11228D20-23ED-4FD5-B969-835921C539FEQ30560287-095DF4D1-F2BA-4DE9-BE60-EA46EBA7CE65Q33388196-CD33EA83-11B1-428B-9B2B-62A6B3AA5662Q33390926-C581D0A8-C248-48FD-9B2B-628818350FECQ33394281-45D0138C-9AB7-48A8-9F92-26A67C3C4B19Q33395607-F3F83FA2-73A3-4358-99ED-C153A29FDCA6Q33711127-B320DF97-5424-4C84-AA8A-B02565B014ABQ34250459-37876E22-D14E-4970-A4DE-DA8334819426Q38255675-EF546FD5-2E37-4682-8E2D-509EAC4B2D30Q38580714-316B5BC3-DE11-4249-8592-4E58C93D7680Q38907743-8DFE0152-3341-46D6-ACC5-0459CA91C84BQ39189407-41184195-0C59-4007-BCDF-DCA0F8355EE2Q40833514-A3D67905-DF19-4402-9910-920931D51334Q40940741-96A7CCC6-5E79-4A1F-9A8E-00EC6FFDB985Q43600412-4FD15E6B-3354-409E-83E7-DEAB32A77E2DQ61820194-04546FBD-ED8D-4B8C-AB0F-6725CBBE48E3Q94480117-E590F264-8C73-48A9-9C46-7EC8292A1EFFQ96118814-EF12D12D-62BC-4A5D-B142-616EA3257506
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Brianna Harris
@ast
Brianna Harris
@en
Brianna Harris
@es
Brianna Harris
@nl
Brianna Harris
@sl
type
label
Brianna Harris
@ast
Brianna Harris
@en
Brianna Harris
@es
Brianna Harris
@nl
Brianna Harris
@sl
altLabel
Brianna N. Harris
@en
prefLabel
Brianna Harris
@ast
Brianna Harris
@en
Brianna Harris
@es
Brianna Harris
@nl
Brianna Harris
@sl
P106
P1153
35722091300
P21
P31
P496
0000-0001-6229-9907